Study:
Phase II Trial of Response-Adapted Chemotherapy Based on Positron Emission Tomography for Non-Bulky Stage I and II Hodgkin Lymphoma
Rationale:
Drugs used in chemotherapy work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Giving more than one
drug (combination chemotherapy) may kill more cancer cells. Radiation therapy uses high
energy x-rays to kill cancer cells. Giving combination chemotherapy together with radiation
therapy may kill more cancer cells and allow doctors to save the part of the body where the
cancer started. Comparing results of diagnostic procedures, such as PET scan, done before,
during, and after chemotherapy may help doctors predict a patient`s response to treatment
and help plan the best treatment.
Purpose:
This phase II trial is studying how well chemotherapy based on PET scan works in
treating patients with stage I or stage II Hodgkin lymphoma.
Study Status: Recruiting
Recruiting:
Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente 866-223-8100
| Condition |
Intervention |
Phase |
|
Lymphoma |
Biological: bleomycin sulfate
Drug: ABVD regimen
Drug: BEACOPP regimen
Drug: cyclophosphamide
Drug: dacarbazine
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: prednisone
Drug: procarbazine hydrochloride
Drug: vinblastine sulfate
Drug: vincristine sulfate
Other: laboratory biomarker analysis
Procedure: computed tomography
Radiation: fludeoxyglucose F 18
Radiation: radiation therapy |
Phase 2 |
Verified by
Cancer and Leukemia Group B
February, 2013
Sponsored by: Cancer and Leukemia Group B
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT01132807
Study Type: Interventional
Study Design: Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
David J. Straus, MD., Principal Investigator